- NVAX +8.54%
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily · 21 hours ago
Open | 12.05 |
High | 12.98 |
Low | 12.02 |
Mkt Cap | 1.91B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 11.94 |
52 Wk. Low | 3.53 |
52 Wk. High | 23.86 |
Related stocks
Company in Gaithersburg, Maryland
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 93.86M | 15.90% ▲ |
Net Income | -147.55M | - |
Diluted EPS | -1.05 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $1.36 | - |
Q1 2024 | -$1.06 | -$1.05 |
Q4 2023 | -$0.45 | -$1.44 |
S&P FuturesES=F | 5,642.00+2.25 (+0.04%) |
Dow FuturesYM=F | 40,147.00+58.00 (+0.14%) |
Nasdaq FuturesNQ=F | 20,433.50-8.25 (-0.04%) |
207.45-0.17% | |
65.71-1.90% | |
60.16+0.74% |